US EditionAbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata with latest results, says GlobalData - GlobalData
Summary by GlobalData
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
AbbVie’s upadacitinib holds potential to cement dominant place in alopecia areata with latest results, says GlobalData - GlobalData
AbbVie recently announced topline results from one of two parallel studies of the pivotal Phase III UP-AA trial evaluating upadacitinib in severe alopecia areata (AA). Upadacitinib’s latest results could provide AbbVie with a dominant place in AA while potentially addressing the need for treatment options with higher efficacy, according to GlobalData, a leading data and analytics company. Vinie Varkey, Healthcare Analyst at GlobalData, comments:…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
